{"success":true,"data":{"pressRelease":{"id":"161884","rtpr_id":"nBwb7F7BCa-20261006","ticker":"TMLCF","exchange":"OTC","all_tickers":["TMLCF","MLCO"],"title":"The More Life Company Advancing U.S. Compounded Pharmaceutical Commercialization Pathway for Quicksome™","author":"Business Wire","published_at":"2026-10-06T12:45:00.222Z","article_body":"The More Life Company Advancing U.S. Compounded Pharmaceutical\nCommercialization Pathway for Quicksome™\n\nStrategic LOI advances U.S. compounding capability for a growing portfolio of\npotential Quicksome-enabled pharmaceutical applications\n\nThe More Life Company Corp. (the “Company” or “MLCO”), (CSE: MLCO)\n(OTC: TMLCF) is pleased to announce that it has entered into a strategic\nletter of intent (“LOI”) with an established U.S. 503A compounding\npharmacy to advance the development, compounding and commercialization of\nQuicksome™-enabled prescription compounded pharmaceutical products in the\nUnited States.\n\nThe contemplated relationship is designed to establish dedicated U.S.\ncompounding capability for Quicksome, combining MLCO’s proprietary\nformulation and delivery technology with an experienced U.S. partner’s\ncompounding, formulation development, pharmacy, dispensing, national\nfulfillment and telemedicine capabilities.\n\nInitial opportunities are being evaluated across hormone replacement, peptides\nand other active compounds, with the potential to support an expanding\nportfolio of Quicksome-enabled products across multiple therapeutic and\nwellness categories.\n\nThe parties to the LOI have mutually agreed not to publicly identify the U.S.\npartner at this stage as they focus on operational readiness, compounding\nimplementation planning, initial business development and completion of\ndefinitive documentation.\n\nKEY TERMS\n\n\n * Proposed Relationship: The parties intend to evaluate the development,\ncompounding and commercialization of mutually approved Quicksome™-enabled\nprescription compounded pharmaceutical products in the United States.\n\n * Commercial Framework: The proposed relationship would include a Quicksome™\ntechnology licensing model and potential exclusivity within the defined U.S.\nprescription-compounding field, with the specific terms to be set out in\ndefinitive documentation.\n\n * Next Steps: The parties will conduct due diligence, evaluate implementation\nrequirements and work toward definitive documentation. Except for certain\ncustomary provisions, the LOI is non-binding.\n\nKEY PROPOSED RELATIONSHIP HIGHLIGHTS\n\n\n * U.S. Compounding Capability: Advancing a dedicated U.S. pathway for the\ndevelopment, compounding and commercialization of Quicksome-enabled\nprescription compounded pharmaceutical products.\n\n * Operational Readiness: Advancing the equipment, facility,\nenvironmental-control and implementation work required to establish dedicated\nQuicksome compounding capability within the partner’s existing U.S. pharmacy\ninfrastructure.\n\n * Expanding Product Portfolio: Initially evaluating hormone replacement,\npeptides and other active compounds where Quicksome may provide meaningful\nformulation, delivery, patient-experience or commercial advantages.\n\n * National Commercial Reach: Leveraging an established U.S. pharmacy platform\nwith national dispensing and fulfillment capabilities and existing\nrelationships across healthcare and telemedicine channels.\n\n * Business Development: Beginning selected discussions with prospective\ncustomers and commercial partners while operational readiness and definitive\ndocumentation advance.\n\nBUILDING ON RECENT QUICKSOME™ TESTOSTERONE RESULTS\n\nThe LOI follows MLCO’s recently announced results from a third-party\nadministered human pharmacokinetic study evaluating United States Pharmacopeia\n(“USP”) grade testosterone formulated using the Company’s Quicksome™\nsublingual delivery technology.\n\nManagement views the study as having provided an important new human\nvalidation point for the Quicksome platform and supports the Company’s\ncontinued work toward differentiated approaches to hormone delivery.\n\nMLCO believes the commercial opportunity extends across hormones, peptides and\nother active compounds, while MLCO’s broader Quicksome development work\nincludes applications such as CoQ10 and other molecules where improved\ndelivery, stability, dose efficiency or user experience may create commercial\nvalue.\n\n“Our work with Quicksome has increasingly pointed us toward a much larger\nopportunity in compounded pharmaceuticals. Developing differentiated\nformulations is only part of that opportunity. We also need the compounding,\npharmacy, dispensing and fulfillment infrastructure capable of bringing those\nproducts into the market,” stated Dennis Hancock, President and Chief\nExecutive Officer of The More Life Company.\n\n“What excites us is that we are not building around a single molecule or\ntherapeutic category. Testosterone provides an important recent human\nvalidation point, while the broader opportunity may extend across hormones,\npeptides and other active compounds where Quicksome may create meaningful\ndifferentiation.”\n\n“We are now bringing the technology, U.S. compounding infrastructure and\ncommercial channels together, and we believe that creates a significant new\nbusiness-development opportunity for The More Life Company.”\n\nQUICKSOME™ BUSINESS DEVELOPMENT EXPANDING\n\nWith this U.S. commercialization pathway advancing, MLCO is expanding\ndiscussions with telemedicine platforms, healthcare organizations,\npharmaceutical developers and other commercial partners interested in\nevaluating Quicksome-enabled applications.\n\nMLCO and its prospective U.S. partner plan to concurrently advance definitive\ndocumentation, operational readiness, detailed equipment and facility\nrequirements, initial product prioritization and selected commercial\ndiscussions.\n\nABOUT QUICKSOME™\n\nQuicksome™ is The More Life Company’s patented desiccated liposomal\nformulation and delivery technology. The platform utilizes proprietary\nformulation approaches and stabilizing molecules to encapsulate and formulate\nactive ingredients into efficient dosage formats designed to support rapid\ndelivery, precision dosing and improved formulation performance.\n\nThe Company is advancing Quicksome across human health applications where\nformulation, stability, bioavailability, dose efficiency, convenience and\nneedle-free delivery represent potential opportunities for innovation.\n\nABOUT THE MORE LIFE COMPANY CORP.\n\nThe More Life Company Corp., formerly Mountain Valley MD Holdings Inc., is\nbuilding a world-class organization centered around the implementation,\nlicensing and reselling of key technologies and formulations:\n\n• patented Quicksome™ oral formulation and delivery technologies;\n\n• patented Quicksol™ solubility formulation technology; and\n\n• licensed product reseller of Agrarius™, a novel agricultural plant\nsignaling technology.\n\nConsistent with its vision towards “More Life”, the Company applies its\nowned and licensed technologies to its work for advanced delivery of molecules\nfor human and husbandry animal applications, including the development of\nproducts for pain management, weight loss, energy, focus, sleep, anxiety, and\nmore. Additionally, the Company’s work with Agrarius is focused on\ngenerating a positive impact on crop yields and reducing fertilizer usage.\n\nThe Company’s patented Quicksome™ technology utilizes proprietary\nformulations and stabilizing molecules to encapsulate and formulate active\ningredients into highly efficient product formats. The result is a new\ngeneration of product formulations that could be capable of delivering\nnutraceutical and drug molecules into the body faster, with greater impact,\nefficiency and accuracy.\n\nThe Company’s patented Quicksol™ technology covers all highly solubilized\nmacrocyclic lactones that could be effectively applied in multiple viral\napplications that could positively impact human and animal health globally.\n\nThe Company’s licensed Agrarius™ agricultural plant signaling technology\nis designed to be applied to crops to naturally increase yields, reduce\nfertilizer usage, and increase general resilience to pests and climate change.\n\nFor more Company information and contact details, visit\nwww.themorelife.company\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.themorelife.company&esheet=54616790&newsitemid=20261006228365&lan=en-US&anchor=www.themorelife.company&index=1&md5=1b8eeb1d3ee9fea584ab263f0ec4629f)\n.\n\nthemorelife.company\n\nCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION\n\nCertain statements contained in this news release may constitute\nforward-looking information within the meaning of applicable securities laws.\nForward-looking information is often, but not always, identified by words such\nas “anticipate”, “believe”, “continue”, “estimate”,\n“expect”, “intend”, “may”, “plan”, “potential”,\n“should”, “will” and similar expressions, or statements that events,\nconditions or results “can”, “could”, “may”, “should” or\n“will” occur or be achieved.\n\nForward-looking information contained in this news release includes, but is\nnot limited to, statements regarding the negotiation and execution of\ndefinitive documentation with the U.S. compounding pharmacy; the establishment\nand operational readiness of dedicated Quicksome compounding capability in the\nUnited States; equipment, facility, environmental-control and implementation\nrequirements; the timing and outcome of any on-site facility readiness; the\ndevelopment of a Quicksome technology licensing model; the evaluation,\nprioritization, development, compounding and commercialization of hormone\nreplacement, peptide, CoQ10 and other Quicksome-enabled applications; the\nexpansion of business-development discussions with prospective customers and\ncommercial partners; and the potential commercial value, differentiation and\nmarket opportunities associated with Quicksome-enabled products.\n\nForward-looking information is based on management’s current expectations,\nassumptions and beliefs as of the date of this news release and is subject to\nknown and unknown risks, uncertainties and other factors that may cause actual\nresults, performance or developments to differ materially from those expressed\nor implied by such forward-looking information. These factors include, among\nothers, the ability of the parties to negotiate and execute definitive\ndocumentation; the outcome of facility, equipment and operational-readiness\nassessments; regulatory, pharmacy, compounding and other requirements\napplicable to contemplated products and activities; the results of future\nformulation, validation and development work; customer and market acceptance;\nthe availability of capital, commercial partners and other resources; and\nother risks associated with the development and commercialization of\npharmaceutical, nutraceutical and delivery technologies.\n\nThere can be no assurance that definitive documentation will be executed, that\nthe contemplated U.S. compounding capability will be established on the timing\nor terms currently anticipated, that any particular Quicksome-enabled\nformulation will be developed or commercialized, that prospective\nbusiness-development discussions will result in commercial arrangements, or\nthat any Quicksome™ formulation will receive applicable regulatory\nauthorization or achieve commercial adoption.\n\nReaders are cautioned not to place undue reliance on forward-looking\ninformation. Any forward-looking information contained in this news release\nrepresents the Company’s expectations as of the date hereof and is subject\nto change after such date. The Company disclaims any intention or obligation\nto update or revise any forward-looking information, whether as a result of\nnew information, future events or otherwise, except as required by applicable\nsecurities legislation.\n\nNeither the CSE nor OTC Markets Group has reviewed or approved the contents of\nthis press release.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261006228365/en/\n(https://www.businesswire.com/news/home/20261006228365/en/)\n\nFor further information:\n\n\n\nDennis Hancock\n\nPresident and Chief Executive Officer\n\nThe More Life Company Corp.\n\nInvestor Relations: 647-725-9755\n\nEmail: info@themorelife.company (mailto:info@themorelife.company)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwb7F7BCa-20261006","title":"The More Life Company Advancing U.S. Compounded Pharmaceutical Commercialization Pathway for Quicksome™","author":"Business Wire","ticker":"TMLCF","created":"2026-10-06T12:45:00.222Z","tickers":["TMLCF","MLCO"],"exchange":"OTC","article_body":"The More Life Company Advancing U.S. Compounded Pharmaceutical\nCommercialization Pathway for Quicksome™\n\nStrategic LOI advances U.S. compounding capability for a growing portfolio of\npotential Quicksome-enabled pharmaceutical applications\n\nThe More Life Company Corp. (the “Company” or “MLCO”), (CSE: MLCO)\n(OTC: TMLCF) is pleased to announce that it has entered into a strategic\nletter of intent (“LOI”) with an established U.S. 503A compounding\npharmacy to advance the development, compounding and commercialization of\nQuicksome™-enabled prescription compounded pharmaceutical products in the\nUnited States.\n\nThe contemplated relationship is designed to establish dedicated U.S.\ncompounding capability for Quicksome, combining MLCO’s proprietary\nformulation and delivery technology with an experienced U.S. partner’s\ncompounding, formulation development, pharmacy, dispensing, national\nfulfillment and telemedicine capabilities.\n\nInitial opportunities are being evaluated across hormone replacement, peptides\nand other active compounds, with the potential to support an expanding\nportfolio of Quicksome-enabled products across multiple therapeutic and\nwellness categories.\n\nThe parties to the LOI have mutually agreed not to publicly identify the U.S.\npartner at this stage as they focus on operational readiness, compounding\nimplementation planning, initial business development and completion of\ndefinitive documentation.\n\nKEY TERMS\n\n\n * Proposed Relationship: The parties intend to evaluate the development,\ncompounding and commercialization of mutually approved Quicksome™-enabled\nprescription compounded pharmaceutical products in the United States.\n\n * Commercial Framework: The proposed relationship would include a Quicksome™\ntechnology licensing model and potential exclusivity within the defined U.S.\nprescription-compounding field, with the specific terms to be set out in\ndefinitive documentation.\n\n * Next Steps: The parties will conduct due diligence, evaluate implementation\nrequirements and work toward definitive documentation. Except for certain\ncustomary provisions, the LOI is non-binding.\n\nKEY PROPOSED RELATIONSHIP HIGHLIGHTS\n\n\n * U.S. Compounding Capability: Advancing a dedicated U.S. pathway for the\ndevelopment, compounding and commercialization of Quicksome-enabled\nprescription compounded pharmaceutical products.\n\n * Operational Readiness: Advancing the equipment, facility,\nenvironmental-control and implementation work required to establish dedicated\nQuicksome compounding capability within the partner’s existing U.S. pharmacy\ninfrastructure.\n\n * Expanding Product Portfolio: Initially evaluating hormone replacement,\npeptides and other active compounds where Quicksome may provide meaningful\nformulation, delivery, patient-experience or commercial advantages.\n\n * National Commercial Reach: Leveraging an established U.S. pharmacy platform\nwith national dispensing and fulfillment capabilities and existing\nrelationships across healthcare and telemedicine channels.\n\n * Business Development: Beginning selected discussions with prospective\ncustomers and commercial partners while operational readiness and definitive\ndocumentation advance.\n\nBUILDING ON RECENT QUICKSOME™ TESTOSTERONE RESULTS\n\nThe LOI follows MLCO’s recently announced results from a third-party\nadministered human pharmacokinetic study evaluating United States Pharmacopeia\n(“USP”) grade testosterone formulated using the Company’s Quicksome™\nsublingual delivery technology.\n\nManagement views the study as having provided an important new human\nvalidation point for the Quicksome platform and supports the Company’s\ncontinued work toward differentiated approaches to hormone delivery.\n\nMLCO believes the commercial opportunity extends across hormones, peptides and\nother active compounds, while MLCO’s broader Quicksome development work\nincludes applications such as CoQ10 and other molecules where improved\ndelivery, stability, dose efficiency or user experience may create commercial\nvalue.\n\n“Our work with Quicksome has increasingly pointed us toward a much larger\nopportunity in compounded pharmaceuticals. Developing differentiated\nformulations is only part of that opportunity. We also need the compounding,\npharmacy, dispensing and fulfillment infrastructure capable of bringing those\nproducts into the market,” stated Dennis Hancock, President and Chief\nExecutive Officer of The More Life Company.\n\n“What excites us is that we are not building around a single molecule or\ntherapeutic category. Testosterone provides an important recent human\nvalidation point, while the broader opportunity may extend across hormones,\npeptides and other active compounds where Quicksome may create meaningful\ndifferentiation.”\n\n“We are now bringing the technology, U.S. compounding infrastructure and\ncommercial channels together, and we believe that creates a significant new\nbusiness-development opportunity for The More Life Company.”\n\nQUICKSOME™ BUSINESS DEVELOPMENT EXPANDING\n\nWith this U.S. commercialization pathway advancing, MLCO is expanding\ndiscussions with telemedicine platforms, healthcare organizations,\npharmaceutical developers and other commercial partners interested in\nevaluating Quicksome-enabled applications.\n\nMLCO and its prospective U.S. partner plan to concurrently advance definitive\ndocumentation, operational readiness, detailed equipment and facility\nrequirements, initial product prioritization and selected commercial\ndiscussions.\n\nABOUT QUICKSOME™\n\nQuicksome™ is The More Life Company’s patented desiccated liposomal\nformulation and delivery technology. The platform utilizes proprietary\nformulation approaches and stabilizing molecules to encapsulate and formulate\nactive ingredients into efficient dosage formats designed to support rapid\ndelivery, precision dosing and improved formulation performance.\n\nThe Company is advancing Quicksome across human health applications where\nformulation, stability, bioavailability, dose efficiency, convenience and\nneedle-free delivery represent potential opportunities for innovation.\n\nABOUT THE MORE LIFE COMPANY CORP.\n\nThe More Life Company Corp., formerly Mountain Valley MD Holdings Inc., is\nbuilding a world-class organization centered around the implementation,\nlicensing and reselling of key technologies and formulations:\n\n• patented Quicksome™ oral formulation and delivery technologies;\n\n• patented Quicksol™ solubility formulation technology; and\n\n• licensed product reseller of Agrarius™, a novel agricultural plant\nsignaling technology.\n\nConsistent with its vision towards “More Life”, the Company applies its\nowned and licensed technologies to its work for advanced delivery of molecules\nfor human and husbandry animal applications, including the development of\nproducts for pain management, weight loss, energy, focus, sleep, anxiety, and\nmore. Additionally, the Company’s work with Agrarius is focused on\ngenerating a positive impact on crop yields and reducing fertilizer usage.\n\nThe Company’s patented Quicksome™ technology utilizes proprietary\nformulations and stabilizing molecules to encapsulate and formulate active\ningredients into highly efficient product formats. The result is a new\ngeneration of product formulations that could be capable of delivering\nnutraceutical and drug molecules into the body faster, with greater impact,\nefficiency and accuracy.\n\nThe Company’s patented Quicksol™ technology covers all highly solubilized\nmacrocyclic lactones that could be effectively applied in multiple viral\napplications that could positively impact human and animal health globally.\n\nThe Company’s licensed Agrarius™ agricultural plant signaling technology\nis designed to be applied to crops to naturally increase yields, reduce\nfertilizer usage, and increase general resilience to pests and climate change.\n\nFor more Company information and contact details, visit\nwww.themorelife.company\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.themorelife.company&esheet=54616790&newsitemid=20261006228365&lan=en-US&anchor=www.themorelife.company&index=1&md5=1b8eeb1d3ee9fea584ab263f0ec4629f)\n.\n\nthemorelife.company\n\nCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION\n\nCertain statements contained in this news release may constitute\nforward-looking information within the meaning of applicable securities laws.\nForward-looking information is often, but not always, identified by words such\nas “anticipate”, “believe”, “continue”, “estimate”,\n“expect”, “intend”, “may”, “plan”, “potential”,\n“should”, “will” and similar expressions, or statements that events,\nconditions or results “can”, “could”, “may”, “should” or\n“will” occur or be achieved.\n\nForward-looking information contained in this news release includes, but is\nnot limited to, statements regarding the negotiation and execution of\ndefinitive documentation with the U.S. compounding pharmacy; the establishment\nand operational readiness of dedicated Quicksome compounding capability in the\nUnited States; equipment, facility, environmental-control and implementation\nrequirements; the timing and outcome of any on-site facility readiness; the\ndevelopment of a Quicksome technology licensing model; the evaluation,\nprioritization, development, compounding and commercialization of hormone\nreplacement, peptide, CoQ10 and other Quicksome-enabled applications; the\nexpansion of business-development discussions with prospective customers and\ncommercial partners; and the potential commercial value, differentiation and\nmarket opportunities associated with Quicksome-enabled products.\n\nForward-looking information is based on management’s current expectations,\nassumptions and beliefs as of the date of this news release and is subject to\nknown and unknown risks, uncertainties and other factors that may cause actual\nresults, performance or developments to differ materially from those expressed\nor implied by such forward-looking information. These factors include, among\nothers, the ability of the parties to negotiate and execute definitive\ndocumentation; the outcome of facility, equipment and operational-readiness\nassessments; regulatory, pharmacy, compounding and other requirements\napplicable to contemplated products and activities; the results of future\nformulation, validation and development work; customer and market acceptance;\nthe availability of capital, commercial partners and other resources; and\nother risks associated with the development and commercialization of\npharmaceutical, nutraceutical and delivery technologies.\n\nThere can be no assurance that definitive documentation will be executed, that\nthe contemplated U.S. compounding capability will be established on the timing\nor terms currently anticipated, that any particular Quicksome-enabled\nformulation will be developed or commercialized, that prospective\nbusiness-development discussions will result in commercial arrangements, or\nthat any Quicksome™ formulation will receive applicable regulatory\nauthorization or achieve commercial adoption.\n\nReaders are cautioned not to place undue reliance on forward-looking\ninformation. Any forward-looking information contained in this news release\nrepresents the Company’s expectations as of the date hereof and is subject\nto change after such date. The Company disclaims any intention or obligation\nto update or revise any forward-looking information, whether as a result of\nnew information, future events or otherwise, except as required by applicable\nsecurities legislation.\n\nNeither the CSE nor OTC Markets Group has reviewed or approved the contents of\nthis press release.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261006228365/en/\n(https://www.businesswire.com/news/home/20261006228365/en/)\n\nFor further information:\n\n\n\nDennis Hancock\n\nPresident and Chief Executive Officer\n\nThe More Life Company Corp.\n\nInvestor Relations: 647-725-9755\n\nEmail: info@themorelife.company (mailto:info@themorelife.company)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-06T12:45:00.25666694Z","server_sent_at_ms":1791290700256},"received_at":"2026-10-06T12:45:00.331Z","source_url":"https://www.businesswire.com/news/home/20261006228365/en/"},"analysis":{"id":"150389","press_release_id":"161884","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["LOI is non-binding; definitive documentation not yet executed","U.S. partner not publicly identified","No financial terms disclosed","Micro-cap issuer with forward-looking commercial claims subject to regulatory and execution risk"],"eventType":"partnership","narrative":"The More Life Company (CSE: MLCO, OTC: TMLCF) signed a letter of intent with an established U.S. 503A compounding pharmacy to develop and commercialize Quicksome™-enabled prescription compounded products in the United States.\n\nThe LOI is non-binding except for customary provisions, and the partner is not being publicly identified at this stage. Initial applications under evaluation include hormone replacement, peptides and other active compounds.\n\nThe deal follows a recently announced human pharmacokinetic study of Quicksome-formulated USP-grade testosterone, which management views as a validation point for the platform. There is no assurance definitive documentation will be executed.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Non-binding LOI gives Quicksome a U.S. compounding commercialization path, but execution risk is high and terms are undisclosed."},"keyFigures":{},"quotedText":"We are now bringing the technology, U.S. compounding infrastructure and commercial channels together, and we believe that creates a significant new business-development opportunity for The More Life Company.","namedEntities":{"people":[{"name":"Dennis Hancock","role":"President and CEO"}],"products":["Quicksome™","Quicksol™","Agrarius™"],"companies":[{"name":"The More Life Company Corp.","ticker":"TMLCF","relationship":"filer"},{"name":"Unnamed U.S. 503A compounding pharmacy","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"A non-binding LOI with an unnamed U.S. 503A compounding pharmacy to commercialize Quicksome products. Early-stage, no financial terms, and definitive documentation is not assured."},"tickerRelevance":{"others":[],"primary":"TMLCF"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap OTC","eventGravity":"non-binding LOI, no financial terms","issuerAuthored":true}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"The More Life Company (CSE: MLCO, OTC: TMLCF) signed a letter of intent with an established U.S. 503A compounding pharmacy to develop and commercialize Quicksome™-enabled prescription compounded products in the United States.\n\nThe LOI is non-binding except for customary provisions, and the partner is not being publicly identified at this stage. Initial applications under evaluation include hormone replacement, peptides and other active compounds.\n\nThe deal follows a recently announced human pharmacokinetic study of Quicksome-formulated USP-grade testosterone, which management views as a validation point for the platform. There is no assurance definitive documentation will be executed.","key_figures":{},"named_entities":{"people":[{"name":"Dennis Hancock","role":"President and CEO"}],"products":["Quicksome™","Quicksol™","Agrarius™"],"companies":[{"name":"The More Life Company Corp.","ticker":"TMLCF","relationship":"filer"},{"name":"Unnamed U.S. 503A compounding pharmacy","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T12:45:06.043Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap OTC","eventGravity":"non-binding LOI, no financial terms","issuerAuthored":true}},"durationMs":5686,"modelName":"glm-5.3-flashx"}}